This article is more than 5 years old. Information may no longer be current.
Apple Heart Study heads arrhythmia highlights from ACC
Click Here to Manage Email Alerts
NEW ORLEANS — The Apple Heart Study, which may change practice in terms of how atrial fibrillation is diagnosed and managed, and the WRAP-IT study, which spotlighted a technology to reduce cardiac device infections, were among the highlights from the American College of Cardiology Scientific Session that should have great implications for the management of arrhythmia disorders.
Read on for a list of arrhythmia content of note from the meeting compiled by Cardiology Today.
Apple Heart Study forms ‘solid foundation’ for AF detection via smartwatch
NEW ORLEANS — Anticipated results of the Apple Heart Study, which evaluated how well a smartwatch can identify and prompt subsequent clinical evaluation, were presented before a packed room at the American College of Cardiology Scientific Session.
Antibacterial envelope reduces rate of cardiac device infections in WRAP-IT
NEW ORLEANS — Wrapping cardiac implantable devices in an antibiotic-eluting envelope, in addition to standard infection prevention strategies, reduced the risk for major device-related infections by approximately 40%, researchers reported at the American College of Cardiology Scientific Session.
Alcohol abstinence reduces arrhythmia recurrences, BP in moderate drinkers with AF
NEW ORLEANS — Lowering the consumption of alcohol intake in moderate drinkers with a history of atrial fibrillation may help lower BP and arrhythmia occurrences, according to findings presented at the American College of Cardiology Scientific Session.
Atrial fibrillation more likely with low-carb diet
NEW ORLEANS — A diet low in carbohydrates may lead to a greater risk for atrial fibrillation, according to findings presented at the American College of Cardiology Scientific Session.
AUGUSTUS: Dual therapy with apixaban, P2Y12 inhibitor safe in Afib patients post-ACS or PCI
An antithrombotic regimen that includes a P2Y12 inhibitor and apixaban (Eliquis, Bristol-Myers Squibb/Pfizer), without aspirin, resulted in less bleeding and fewer hospitalizations, with no difference in ischemic events compared with other regimens that included a vitamin K antagonist, aspirin or both in patients with atrial fibrillation who had ACS or PCI.